Cardiovascular disease, especially coronary heart disease (CHD), is the main cause of mortality and morbidity in type 2 diabetesMajor trials have shown that a number of interventions are highly effective in reducing major outcomes including death; their effects are additive
HypertensionHypertension is common in diabetes; its greatest impact is on microvascular, cerebrovascular and heart failure end points, with less effect on MI and peripheral vascular disease. Tight control of hypertension in UKPDS reduced the risk of macrovascular outcomes, particularly stroke and congestive heart failure (CCF) but the reduction in MI was not significant. Atenolol and captopril were equally effective. The ABCD, FACET and HOPE trials all showed that angiotensinconverting enzyme inhibitors (ACEIs) prevent cardiovascular events in diabetes. An analysis of 45,000 patients showed that beta-blockers also prevent MI. 14 ACEIs are well tolerated and angiotensin II receptor antagonists (AIIRAs), introduced since these trials, may be combined with them.The importance of checking renal function after initiating either class of drug cannot be overemphasised. Renovascular disease is common in type 2 diabetes. Doxazosin increased the risk of CCF in the large ALLHAT trial, so is not recommended for first-line use. Hypertension associated with microalbuminuria or established nephropathy should be treated as volume expanded (renal) hypertension; loop diuretics are often required.
MicroalbuminuriaA small increase in urinary protein excretion (microalbuminuria) is a precursor to renal failure from diabetic nephropathy and indicates a high risk of CHD and premature death. This risk increases in parallel with the degree of proteinuria. While increasing numbers of type 2 patients are going on to dialysis, they have poor outcome because of cardiovascular disease. Therefore, the dual aim in proteinuric patients is to prevent cardiovascular events and preserve renal function. ACEIs and AIIRAs both reduce progression of microalbuminuria to established nephropathy, retard deterioration of renal function and improve survival (combined end point) in patients with heavy proteinuria. It is less clear whether AIIRAs influence cardiovascular death.Microalbuminuria has other causes, including urine infection and most renal and renal tract pathologies, pyrexia, recent exertion and uncontrolled heart failure.
Left ventricular hypertrophyLeft ventricular hypertrophy, an independent predictor of coronary events, has been used as an end point in some studies.
Haemostatic factors
Metabolic syndromeThe term 'metabolic syndrome' refers to a group of related disorders in which insulin resistance is combined with one or more of the following features: obesity, type 2 diabetes, essential hypertension, hypertriglyceridaemia, low HDL cholesterol and microalbuminuria.This concept has altered our perception of type 2 diabetes from a primary disorder to a syndrome with insulin resistance the central feature and a major impact on the vasculature. It remains unclear whether i...